Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects

Cancer Research

Volumn 63, Issue 5, 2003, Pages 1130-1137

  Hendriks, Bart S ^a   Opresko, Lee K ^c   Wiley, H Steven ^c   Lauffenburger, Douglas ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CONTROLLED STUDY; DIMERIZATION; GENE ACTIVATION; GENE CONTROL; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR MECHANICS; ONCOGENE NEU; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROVIRUS INFECTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; VALIDATION PROCESS;

BREAST; CELLS, CULTURED; EPITHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0037374022     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Menard, S., Casalini, P., Campiglio, M., Pupa, S., Agresti, R., and Tagliabue, E. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann. Oncol., 12: S15-S19, 2001.
2. Yarden, Y., and Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Moi. Cell. Biol., 2: 127-137, 2001.
3. Riese, D. J., and Stern, D. F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays, 20: 41-48, 1998.
4. Alroy, I., and Yarden, Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett., 410: 83-86, 1997.
5. Hamilton, A., and Piccart, M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2,p53, and BCL-2. Ann. Oncol., 11: 647-663, 2000.
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
7. Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., and Horne, C. H. W. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res., 49: 2087-2090, 1989.
8. Chazin, V. R., Kaleko, M., Miller, A. D., and Slamon, D. J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene, 7: 1859-1866, 1992.
9. DiFiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in N1H/3T3 cells. Science (Wash. DC), 237: 178-182, 1987.
10. Brandt, B. H., Roetger, A., Dittmar, T., Nikolia, G., Seeling, M., Merschjann, A., Nofer, J-R., Dehmer-Moller, G., Junker, R., Assmann, G., and Zaenker, K. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J., 13: 1939-1950, 1999.
11. Spencer, K. S. R., Graus-Porta, D., Leng, J., Hynes, N., and Klemke, R. L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J. Cell Biol., 148: 385-397, 2000.
12. Ignatoski, K. M. W., Lapointe, A. J., Radany, E. H., and Ethier, S. P. erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology, 140: 3615-3622, 1999.
13. Wiechen, K., Karaaslan, S., and Dietel, M. Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells. Int. J. Cancer. 83: 409-411, 1999.
14. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta. 1198: 165-184, 1994.
15. Fazioli, F., Kim, U-H., Rhee, S. G., Molloy, C. J., Segatto, O., and DiFiore, P. P. The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-γ and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol. Cell. Biol., 11: 2040-2048, 1991.
16. Janes, P. W., Daly, R. J., deFazio, A., and Sutherland, R. L. Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2. Oncogene, 9: 3601-3608, 1994.
17. Muthuswamy, S., and Muller, W. J. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene, 11: 271-279, 1995.
18. Ricci, A., Lanfrancone, L., Chiari, R., Belardo, G., Petrica, C., Natali, P., and Pelicci, P. Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene, 11: 1519-1529, 1995.
19. Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., and Yarden, Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J., 15: 254-264, 1996.
20. Worthylake, R., Opresko, L. K., and Wiley, H. S. ErbB-2 Amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem., 274: 8865-8874, 1999.
21. Wiley, H. S., and Burke, P. M. Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic, 2: 12-18, 2001.
22. Wiley, H. S. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J. Cell Biol., 107: 801-810, 1988.
23. Kurten, R. C., Cadena, D. L., and Gill, G. N. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science (Wash. DC), 272: 1008-1010, 1996.
24. French, A. R., Sudlow, G. P., Wiley, H. S., and Lauffenburger, D. A. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J. Biol. Chem., 269: 15749-15755, 1994.
25. Lenferink, A. E. G., Pinkas-Kramarski, R., Poll, M. L. M. v. d. Vugt, M. J. H. v., Klapper, L. N., Tzahar, E., Waterman, H., Sela, M., Zoelen, E. J. J. v., and Yarden, Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J., 17: 3385-3397, 1998.
26. Waterman, H., Sabanai, I., Geiger, B., and Yarden, Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem., 273: 13819-13827, 1998.
27. Carraway, K. L., and Sweeney, C. Localization and modulation of ErbB receptor tyrosine kinase. Curr. Opin. Cell Biol., 13: 125-130, 2001.
28. Ceresa, B. P., and Schmid, S. L. Regulation of signal transduction by endocytosis. Curr. Opin. Cell Biol., 12: 204-210, 2000.
29. Leof, E. B. Growth factor receptor signalling: location, location, location. Trends Cell Biol., 10: 343-348, 2000.
30. Burke, P. M., Schooler, K., and Wiley, H. S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell, 12: 1897-1910, 2001.
31. Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755-7760, 1984.
32. Burke, P. M., and Wiley, H. S. Human mammary epithelial cells rapidly exchange empty EGFR between surface and intracellular pools. J. Cell. Physiol., 180: 448-460, 1999.
33. Band, V., and Sager, R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc. Natl. Acad. Sci. USA. 86: 1249-1253, 1989.
34. Eming, S., Lee, J., Snow, R., Tompkins, R., Yarmush, M., and Morgan, J. Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice: implications for the use of genetically modified keratinocytes to modulate dermal regeneration. J. Investig Dermatol., 1995.
35. Danos, O., and Mulligan, R. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA, 85: 6460-6464, 1988.
36. Wiley, H. S., and Cunningham, D. D. The endocytotic rate constant. J. Biol. Chem., 257: 4222-4229, 1982.
37. Lund, K. A., Opresko, L. K., Starbuck, C., Walsh, B. J., and Wiley, H. S. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J. Biol. Chem., 265: 15713-15723, 1990.
38. French, A. R., Tadaki, D. K., Niyogi, S. K., and Lauffenburger, D. A. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem., 270: 4334-4340, 1995.
39. Lauffenburger, D. A., and Linderman, J. J. Receptors. New York: Oxford University Press. Inc., 1993, ch. 3, pp. 73-132.
40. Starbuck, C., Wiley, H. S., and Lauffenburger, D. A. Epidermal growth factor binding and trafficking dynamics in fibroblasts: relationship to cell proliferation. Chem. Eng. Sci., 45: 2367-2373, 1990.
41. Reddy, C. C., Wells, A., and Lauffenburger, D. A. Proliferative response of fibroblasts expressing internalization-deficient epidermal growth factor (EGF) receptors is altered via differential EGF depletion effect. Biotechnol. Prog., 10: 377-384, 1994.
42. Fendly, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., and Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50: 1550-1558, 1990.
43. Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., Fendly, B. M., Bauer, K. D., and Sliwkowski, M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence of the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56: 1457-1465, 1996.
44. Baselga, J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell, 2: 93-95, 2002.
45. Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G., and Gill, G. N. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem., 266: 11083-11094, 1991.
46. Opresko, L., Chang, C., Will, B., Burke, P. M., Gill, G. N., and Wiley, H. S. Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of tyrosine kinase domain. J. Biol. Chem., 270: 4325-4333, 1995.
47. Wiley, H. S., and Kaplan, J. Epidermal growth factor rapidly induces a redistribution of transferrin receptor pools in human fibroblasts. Proc. Natl. Acad. Sci. USA, 81: 7456-7460, 1984.
48. Herbst, J. J., Opresko, L. K., Walsh, B. J., Lauffenburger, D. A., and Wiley, H. S. Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J. Biol. Chem., 269: 12865-12873, 1994.
49. Ignatoski, K. W., Maehama, T., Markwart, S., Dixon, J., Livant, D., and Ethier, S. ErbB-2 overexpression confers P13′ kinase-dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer, 82: 666-674, 2000.
50. Baulida, J., Kraus, M. H., Alimandi, M., DiFiore, P. P., and Carpenter, G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem., 271: 5251-5257, 1996.
51. Sorkin, A., DiFiore, P. P., and Carpenter, G. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene. 8: 3021-3028, 1993.
52. French, A. R., and Lauffenburger, D. A. Intracellular receptor/ligand sorting based on endosomal retention components. Biotechnol Bioeng., 51: 281-297, 1996.
53. Chen, P., Murphy-Ullrich, J., and Wells, A. A role for gelsolin in actuating epidermal growth factor receptor-mediated cell motility. J. Cell Biol., 134: 689-698, 1996.
54. Glading, A., Uberall, F., Keyse, S. M., Lauffenburger, D. A., and Wells, A. Membrane proximal ERK Signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J. Biol. Chem., 276: 23341-23348, 2001.
55. Glading, A., Chang, P., Lauffenburger, D. A., and Wells, A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J. Biol. Chem., 275: 2390-2398, 2000.
56. Haugh, J. M., Schooler, K., Wells, A., Wiley, H. S., and Lauffenburger, D. A. Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-γ1 signaling pathway. J. Biol. Chem., 274: 8958-8965, 1999.